Vanguard Capital Management
ADPT icon

Vanguard Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Vanguard Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
6,403,587
+309,443
+5% +$4.74M ﹤0.01% 1374
2026
Q1 		$84.6M Buy
+6,094,144
New +$97.1M ﹤0.01% 1569

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's ADPT Position: Q2 2026 in Review

Vanguard Capital Management increased its Adaptive Biotechnologies (ADPT) stake by 5.1% in Q2 2026, buying an estimated $4.74M and bringing the position to 6,403,587 shares worth $137M. The position accounts for ﹤0.01% of the portfolio, ranked #1374.

Vanguard Capital Management first reported a position in ADPT in Q1 2026 and has held it in 2 quarters since. 299 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Vanguard Capital Management held 6,403,587 shares of Adaptive Biotechnologies worth $137M as of Q2 2026.
  • Vanguard Capital Management bought 309,443 Adaptive Biotechnologies shares in Q2 2026, an estimated $4.74M.
  • Adaptive Biotechnologies made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1374 holding.
  • Vanguard Capital Management first reported a position in Adaptive Biotechnologies in Q1 2026 and has held it in 2 quarters since.
  • 299 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.